<DOC>
	<DOCNO>NCT01151410</DOCNO>
	<brief_summary>The purpose study evaluate randomize , double-blind fashion , long-term safety , tolerability efficacy profile aliskiren compare active comparator enalapril child , 6 - 17 year old hypertension ( msSBP ≥ 95th percentile age , gender height , baseline study CSPP100A2365 ) . Patients randomize receive either aliskiren enalapril . Weight-group base dos aliskiren enalapril administer daily child receive study medication double-blind manner . This study conduct support monotherapy registration aliskiren treatment hypertension pediatric patient 6-17 year age ( age baseline Study CSPP100A2365 ) .</brief_summary>
	<brief_title>An Extension Study Evaluate Long Term Safety , Tolerability Efficacy Aliskiren Compared Enalapril Pediatric Hypertensive Patients 6-17 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<criteria>msSBP ( mean 3 systolic blood pressure measurement ) must ≥ 95th percentile age , gender height , Visit 2 ( randomization ) , study CSPP100A2365 Must ≥ 20 kg ≤ 150 kg Visit 2 ( randomization ) , study CSPP100A2365 Must able swallow minitablets ( 2mm diameter ) administer soft food Successful completion Phase 1 ( dose response phase ) least 1 week Phase 2 ( placebo withdrawal phase ) CSPP100A2365 protocol , serious drugrelated adverse event ( ) . Patient receive immunosuppressant medication ( e.g . cyclosporine , MMF , etc ) oral/topical steroid , medical condition Current diagnosis heart failure ( NYHA Class IIIV ) history cardiomyopathy obstructive valvular disease msSBP ≥ 25 % 95th percentile Second third degree heart block without pacemaker AST/SGOT ALT/SGPT &gt; 3 time upper limit reference range Total bilirubin &gt; 2 time upper limit reference range Creatinine clearance &lt; 30 mL/min/1.73m² ( calculate use Modified Schwartz formula estimate glomerular filtration rate [ GFR ] ) , base serum creatinine concentration obtain screen visit ) WBC count &lt; 3000/mm³ Platelet count &lt; 100,000/mm³ Serum potassium &gt; 5.2 mEq/L Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Pediatric hypertension</keyword>
	<keyword>primary hypertension</keyword>
	<keyword>secondary</keyword>
	<keyword>hypertension</keyword>
</DOC>